PYXS PYXIS ONCOLOGY INC

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences.

  • 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ET



  • Jefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET



A live webcast and replay of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, .

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.

To learn more, visit  or follow us on  and .

Pyxis Oncology Contact

Pamela Connealy

CFO and COO



EN
14/05/2025

Underlying

PYXSPYXIS ONCOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PYXIS ONCOLOGY INC

 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provid...

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who...

21h / 1m 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Pyxis Oncology to Participate in Two Upcoming Investor Conferences BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05...

May 14, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Presents Promising Preclinical Results Providing Proof ...

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO’s mechanism Combinati...

April 25, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Onco...

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 11:30 a.m. ET. The Company will also be holding one-on-one investor meetings at the event. A live webcast and ...

April 2, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Present New Preclinical Data Supporting Development ...

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potential patient response Combination of a mouse analog of MICVO and a mouse anti-PD-1 therapy in a syngeneic model resulted in significantly greater tumor regression than either treatment alone Company advances MICVO into monotherapy and comb...

March 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch